Given that HER3 upregulation is an important mechanism of acquired resistance to HER2-targeted therapies in breast cancer patients, we suggest that JAM-A antagonists merit future investigation for potential bioactivity in overcoming resistance to HER2-targeted therapies. The gene discussed is ERBB2; the disease is breast carcinoma.